DexCom, Inc. (DXCM) Debt to Equity Ratio: 0.51
Is DexCom, Inc.’s debt to equity ratio high or low?
DexCom, Inc.'s debt to equity ratio of 0.51 is 50% below its 5-year average of 1.01, near the low end of its 5-year range (0.51–1.25).
As of Thursday, June 11, 2026. 41.38% below its 12-month average of 0.87.
DXCM Debt to Equity Ratio Chart
DXCM Average Debt to Equity Ratio Chart
DXCM Current vs Average Debt to Equity Ratio Chart
DXCM Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.51
DEBT TO EQUITY RATIO AVG TTM
0.87
DEBT TO EQUITY RATIO AVG 3Y
1.00
DEBT TO EQUITY RATIO AVG 5Y
1.01
DEBT TO EQUITY RATIO AVG 10Y
0.89
DEBT TO EQUITY RATIO AVG 15Y
0.62
DEBT TO EQUITY RATIO AVG 20Y
0.99
CURRENT VS TTM AVG
-41.38%
CURRENT VS 3Y AVG
-49.00%
CURRENT VS 5Y AVG
-49.59%
CURRENT VS 10Y AVG
-42.40%
CURRENT VS 15Y AVG
-17.99%
CURRENT VS 20Y AVG
-48.38%
DXCM Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $28.92B | 0.51 | 0.87 | 1.00 | 1.01 |
| Biogen Inc. (BIIB) | $28.94B | 0.38 | 0.39 | 0.44 | 0.53 |
| IQVIA Holdings Inc. (IQV) | $30.08B | 2.49 | 2.41 | 2.34 | 2.26 |
| Medline Inc. (MDLN) | $30.90B | 1.17 | 1.09 | 0.79 | 0.79 |
| Veeva Systems Inc. (VEEV) | $26.31B | 0.01 | 0.01 | 0.01 | 0.02 |
| Centene Corporation (CNC) | $32.26B | 0.94 | 0.84 | 0.83 | 0.81 |
| Zoetis Inc. (ZTS) | $34.27B | 2.85 | 2.13 | 1.86 | 1.81 |
| Waters Corporation (WAT) | $23.21B | 0.58 | 0.76 | 1.73 | 2.93 |
| Mettler-Toledo International Inc. (MTD) | $22.82B | -99.14 | 48.23 | 26.06 | 17.96 |
| BioNTech SE (BNTX) | $22.39B | 0.01 | 0.01 | 0.01 | 0.04 |
Financial Health
Debt/Equity
0.51
Current Ratio
1.88
DexCom, Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for DexCom, Inc. (DXCM)?
- The debt to equity ratio for DXCM stock is 0.51.
- Is DexCom, Inc.'s debt to equity ratio high or low?
- DexCom, Inc.'s debt to equity ratio of 0.51 is 50% below its 5-year average of 1.01, near the low end of its 5-year range (0.51–1.25).
- What is the TTM average debt to equity ratio for DexCom, Inc. (DXCM)?
- The TTM average debt to equity ratio for DXCM stock is 0.87.
- What is the 3Y average debt to equity ratio for DexCom, Inc. (DXCM)?
- The 3Y average debt to equity ratio for DXCM stock is 1.00.
- What is the 5Y average debt to equity ratio for DexCom, Inc. (DXCM)?
- The 5Y average debt to equity ratio for DXCM stock is 1.01.
- What is the 10Y average debt to equity ratio for DexCom, Inc. (DXCM)?
- The 10Y average debt to equity ratio for DXCM stock is 0.89.
- What is the 15Y average debt to equity ratio for DexCom, Inc. (DXCM)?
- The 15Y average debt to equity ratio for DXCM stock is 0.62.
- What is the 20Y average debt to equity ratio for DexCom, Inc. (DXCM)?
- The 20Y average debt to equity ratio for DXCM stock is 0.99.
DexCom, Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.51 |
| 2024-12-31 | 1.23 |
| 2023-12-31 | 1.25 |
| 2022-12-31 | 1.01 |
| 2021-12-31 | 1.06 |
| 2020-12-31 | 1.01 |
| 2019-12-31 | 1.31 |
| 2018-12-31 | 1.53 |
| 2017-12-31 | 0.80 |
| 2016-12-31 | 0.02 |
| 2015-12-31 | 0.01 |
| 2014-12-31 | 0.03 |
| 2013-12-31 | 0.08 |
| 2012-12-31 | 0.09 |
| 2011-12-31 | 0.00 |
| 2010-12-31 | 0.01 |
| 2007-12-31 | 8.77 |
| 2006-12-31 | 0.05 |
| 2005-12-31 | 0.00 |
| 2004-12-31 | 0.00 |
| 2003-12-31 | 0.00 |
| 2002-12-31 | 0.00 |
| 2001-12-31 | 0.00 |
| 2000-12-31 | 0.00 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach